Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

21.75 +0.03 (+0.14%)
Streaming Delayed Price Updated: 10:16 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
4 Analysts Have This to Say About Beam Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside' ↗
 
Via Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday ↗
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close... 
Via Benzinga
News headline image
7 ‘Next Big Things’ for Investors to Buy for 2023 ↗
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
News headline image
Beam Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy ↗
 
Via Benzinga
News headline image
Why Beam Therapeutics Stock Is Falling Today ↗
Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗
 
Via Benzinga
News headline image
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics: Q3 Earnings Insights ↗
Beam Therapeutics (NASDAQ:BEAM) reported its Q3 earnings results on Monday, November 7, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗
 
Via Benzinga
News headline image
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via GlobeNewswire
News headline image
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
News headline image
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
A Sitcom Character Inspired This Investor ↗
Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock. 
Via The Motley Fool
News headline image
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Unity Software, Amazon, Doximity And Other Big Gainers From Friday ↗
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why Beam Therapeutics Stock Is Falling Today ↗
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Monday after the company reported earnings results that were down year-over-year. 
Via Benzinga
News headline image
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
News headline image
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
ON Semiconductor, Global Payments And Other Big Losers From Monday ↗
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection ↗
 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.